BioSig Technologies, Inc., a medical technology company, engages in developing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace.
Adequate balance sheet with weak fundamentals.
Share Price & News
How has BioSig Technologies's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BSGM's share price has been volatile over the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: BSGM exceeded the US Medical Equipment industry which returned 13.1% over the past year.
Return vs Market: BSGM exceeded the US Market which returned 9.2% over the past year.
Price Volatility Vs. Market
How volatile is BioSig Technologies's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StWhat Kind Of Shareholder Owns Most BioSig Technologies, Inc. (NASDAQ:BSGM) Stock?
2 months ago | Simply Wall StWho Has Been Buying BioSig Technologies, Inc. (NASDAQ:BSGM) Shares?
4 months ago | Simply Wall StCould BioSig Technologies, Inc.'s (NASDAQ:BSGM) Investor Composition Influence The Stock Price?
Is BioSig Technologies undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate BSGM's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate BSGM's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: BSGM is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: BSGM is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BSGM's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BSGM is overvalued based on its PB Ratio (19.4x) compared to the US Medical Equipment industry average (3.8x).
How is BioSig Technologies forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BioSig Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine BioSig Technologies's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Explore growth companies in the Healthcare industry.
How has BioSig Technologies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BSGM is currently unprofitable.
Growing Profit Margin: BSGM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BSGM is unprofitable, and losses have increased over the past 5 years at a rate of -26.2% per year.
Accelerating Growth: Unable to compare BSGM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BSGM is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (7.2%).
Return on Equity
High ROE: BSGM has a negative Return on Equity (-257.64%), as it is currently unprofitable.
How is BioSig Technologies's financial position?
Financial Position Analysis
Short Term Liabilities: BSGM's short term assets ($16.6M) exceed its short term liabilities ($1.6M).
Long Term Liabilities: BSGM's short term assets ($16.6M) exceed its long term liabilities ($201.3K).
Debt to Equity History and Analysis
Debt Level: BSGM is debt free.
Reducing Debt: BSGM had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BSGM has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: BSGM has less than a year of cash runway if free cash flow continues to reduce at historical rates of 34.4% each year
What is BioSig Technologies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BSGM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BSGM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BSGM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BSGM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BSGM's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ken Londoner (51yo)
Mr. Kenneth L. Londoner, also known as Ken, MBA, founded BioSig Technologies, Inc. in 2009 and has been its Chief Executive Officer since July 2017. Mr. Londoner has been Managing Partner of Endicott Manag ...
CEO Compensation Analysis
Compensation vs Market: Ken's total compensation ($USD5.03M) is above average for companies of similar size in the US market ($USD1.35M).
Compensation vs Earnings: Ken's compensation has increased whilst the company is unprofitable.
|Chief Financial Officer||2.42yrs||US$2.07m||2.59% $7.7m|
|Chief Scientist||11.33yrs||US$243.75k||no data|
|Vice President of Administration||no data||US$147.00k||0.15% $430.2k|
|Vice President of Investor Relations||0.67yr||no data||no data|
|Vice President of Sales||1.33yrs||no data||0.43% $1.3m|
|Senior Director of Marketing||0.92yr||no data||no data|
|Executive Vice President||3.08yrs||no data||no data|
Experienced Management: BSGM's management team is considered experienced (2.4 years average tenure).
|Independent Director||4.67yrs||US$181.88k||0.49% $1.4m|
|Lead Independent Director||1.42yrs||US$514.46k||0.83% $2.5m|
|Independent Director||1.08yrs||US$169.38k||0.41% $1.2m|
|Member of Advisory Board||2.25yrs||no data||no data|
|Independent Director||5.08yrs||US$214.81k||0.076% $226.8k|
|Independent Director||2.58yrs||US$226.50k||0.38% $1.1m|
|Member of Advisory Board||2.08yrs||no data||no data|
|Independent Director||5.92yrs||US$214.81k||0.21% $624.8k|
|Member of Advisory Board||2.25yrs||no data||no data|
Experienced Board: BSGM's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: BSGM insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 24.9%.
BioSig Technologies, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: BioSig Technologies, Inc.
- Ticker: BSGM
- Exchange: NasdaqCM
- Founded: 2009
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$296.599m
- Shares outstanding: 26.16m
- Website: https://www.biosig.com
Number of Employees
- BioSig Technologies, Inc.
- 54 Wilton Road
- 2nd Floor
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BSGM||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Oct 2014|
BioSig Technologies, Inc., a medical technology company, engages in developing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace. The company’s first product, PURE EPTM System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. The system is indicated for use under the supervision of licensed healthcare practitioners who are responsible for interpreting the data. This novel cardiac signal acquisition and display system is engineered to assist electrophysiologists in clinical decision-making during electrophysiology procedures in patients with abnormal heart rates and rhythms. The company has partnered with Minnetronix on technology development and received FDA 510(k) clearance for the PURE EPTM System in August 2018. It is also developing a library of software tools that are designed to be configured to fit the needs of electrophysiologists in various settings and for arrhythmia treatments. The company was founded in 2009 and is headquartered in Westport, Connecticut.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/06/04 14:18|
|End of Day Share Price||2020/06/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.